ProfileGDS5678 / 1426603_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 63% 66% 65% 64% 63% 62% 63% 59% 71% 64% 65% 63% 64% 63% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.830563
GSM967853U87-EV human glioblastoma xenograft - Control 24.0125166
GSM967854U87-EV human glioblastoma xenograft - Control 33.88465
GSM967855U87-EV human glioblastoma xenograft - Control 43.8037964
GSM967856U87-EV human glioblastoma xenograft - Control 53.7478963
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7699462
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8162863
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5607459
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.519171
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8246364
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8921565
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.7770563
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.8264364
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7931563